Product Information
SYMLINPEN 60 PEN INJECTOR is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $330.9522 per ML under NDC 00310661502. Its NADAC has been published 348 times since May 20, 2015.
FDA first approved this application on Mar 16, 2005.
Strength
1000 ug/mL
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00310661502
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
6/18/2025
Active Ingredients
PRAMLINTIDE ACETATEApproval Type
New Drug (NDA)
FDA Application
NDA021332FDA Approved
3/16/2005
On Market Since
1/8/2015
Pharmacological Classes
Price Statistics
The NADAC for SYMLINPEN 60 PEN INJECTOR has been published 348 times since May 20, 2015, and over the history we have for it it has risen 74.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $330.9522 per ML |
|---|---|
| All-time high | $331.5452 (Jun 11, 2025) |
| All-time low | $189.2783 (May 20, 2015) |
| 52-week high | $330.9522 |
| 52-week low | $330.9522 |
| Median price | $284.9175 |
| Average price | $279.1658 |
| Largest weekly change | +15.0% (Jun 22, 2016) |
| Weeks tracked | 348 |
| Tracking since | May 20, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
0.0%
1Y
0.0%
3Y
+12.8%
5Y
+12.8%
All
+74.8%
Last surveyed Jun 10, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 34% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AstraZeneca Pharmaceuticals LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
pramlintide acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SYMLINPEN 60 PEN INJECTOR?
The current National Average Drug Acquisition Cost (NADAC) for SYMLINPEN 60 PEN INJECTOR, manufactured by AstraZeneca Pharmaceuticals LP, is $330.9522 per ML (NDC 00310661502), effective Jun 10, 2026.
How has the price of SYMLINPEN 60 PEN INJECTOR changed over time?
Over the history we have for it, the NADAC for SYMLINPEN 60 PEN INJECTOR has risen 74.8%. It has been tracked across 348 weekly CMS publications since May 20, 2015.
What are the highest and lowest recorded NADAC prices for SYMLINPEN 60 PEN INJECTOR?
Since May 20, 2015, the NADAC for SYMLINPEN 60 PEN INJECTOR has ranged from a low of $189.2783 (May 20, 2015) to a high of $331.5452 (Jun 11, 2025), with a median of $284.9175 per ML.
Are there cheaper alternatives to SYMLINPEN 60 PEN INJECTOR?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SYMLINPEN 120 PEN INJECTOR, is $217.5214 per ML — about 34% below SYMLINPEN 60 PEN INJECTOR.
Who manufactures SYMLINPEN 60 PEN INJECTOR?
SYMLINPEN 60 PEN INJECTOR (NDC 00310661502) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.